Artificial and natural radioactivity in edible mushrooms from Sao Paulo, Brazil

Environmental biomonitoring has demonstrated that organisms such as crustaceans, fish and mushrooms are useful to evaluate and monitor both ecosystem contamination and quality. Particularly, some mushroom species have a high capacity to retain radionuclides and some toxic elements from the soil and the air. The potential of mushrooms to accumulate radionuclides in their fruit-bodies has been well documented. However, there are no studies that determine natural and artificial radionuclide composition in edible mushrooms, in Brazil. Artificial (137Cs) and natural radioactivity (40K, 226Ra, 228Ra) were\ud determined in 17 mushroom samples from 3 commercialized edible mushroom species. The edible mushrooms collected were Agaricus sp., Pleurotus sp. and Lentinula sp. species. The activity measurements were carried out by gamma spectrometry. The levels of 137Cs varied from 1.45 0.04 to 10.6 0.3 Bq kg 1, 40K levels varied from 461 2 to 1535 10 Bq kg 1, 226Ra levels varied from 14 3 to 66 12 Bq kg 1 and 228Ra levels varied from 6.2 0.2 to 54.2 1.7 Bq kg 1. 137Cs levels in Brazilian mushrooms are in accordance with the radioactive fallout in the Southern Hemisphere. The artificial and natural activities determined in this study were found to be below the maximum permissible levels as\ud established by national legislation. Thus, these mushroom species can be normally consumed by the population without any apparent risks to human health

Infecção natural por tripanosomatídeos (Kinetoplastida: Trypanosomatidae) em Lutzomyia umbratilis (Diptera: Psychodidae) em áreas de leishmaniose tegumentar americana no Amazonas, Brasil

Durante o período de 2002 a 2003 foram realizadas coletas de flebotomíneos em duas áreas do estado do Amazonas (Base de treinamento militar - BI1 e Tarumã Mirim). Nessas coletas foram capturadas um total de 1.440 fêmeas de Lutzomyia (Nyssomyia) umbratilis. Lu.umbratilis é a principal responsável pela transmissão da Leishmaniose Tegumentar Americana (LTA) ao norte do Rio Amazonas. Do total coletado apenas 15 espécimens (ou 1,04%) apresentaram infecção natural por tripanosomatídeos, sendo 12 na BI1 e 3 em Tarumã-Mirim. Isso representou uma taxa de infecção de 1,66% (12 dos 720 capturados em BI1) e 0,42% (3 dos 720 em Tarumã-Mirim). Estes resultados confirmam as informações prévias por outros autores de reduzidos valores de infecção natural por tripanosomatídeos em flebotomíneos, mesmo em áreas altamente endêmicas para leishmaniose.During the period of 2002 to 2003, there were collected sand flies in two areas of Amazon State (Forest Combat Training Base - BI1 and Tarumã-Mirim). Were collected the 1440 L. (Nyssomyia) umbratilis female. Lu. umbratilis is the main responsible for the transmission of American Tegumentary Leishmaniasis (ATL) in the northern of Amazon River. Only 15 specimens (or 1,04%) presented natural infection with trypanosomatids, being 12 at Bl1 and 3 at Tarumã-Mirim. The infection rate was 1,66% (12 of the 720 collected at BI1) and 0,42% (3 of the 720 at Tarumã-Mirim). These results confirm the previous informations described by other authors that insects have low rates of natural infection by trypanosomatids even in high endemic areas for Leishmaniasis

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema : Subgroup analysis of the MEAD study

Background: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously treated DME. Methods: Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34.68 Early Treatment Diabetic Retinopathy Study letters (20/200.20/50 Snellen equivalent), and central retinal thickness (CRT) 65300 \u3bcm measured by time-domain optical coherence tomography. Patients were randomized to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The primary endpoint was 6515-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at study entry. Results: Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n=261) patients were similar. In the previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of DEX 0.7 patients versus 11.1 % of sham had 6515-letter BCVA gain from baseline at study end (P = 0.002), mean average BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average CRT change from baseline was -126.1 \u3bcm with DEX 0.7 versus -39.0 \u3bcm with sham(P < 0.001). Cataract-related adverse events were reported in 70.3 % of baseline phakic patients in the previously treated DEX 0.7 subgroup; vision gains were restored following cataract surgery. Conclusions: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies. The safety profile of DEX 0.7 in previously treated patients was similar to its safety profile in the total study population